Clinical trial
Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients
NCT00211952 · Medical University of Gdansk, Other · Suspended
Key facts
| NCT number | NCT00211952 |
|---|---|
| Title | Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients |
| Official title | A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients |
| Lead sponsor | Medical University of Gdansk, Other |
| Collaborators | Central and Eastern European Oncology Group Stowarzyszenie Ludzi Wyleczonych z Raka Płuca Pharmacia Industry |
| Status | Suspended |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | celecoxib |
| Enrollment | 542 |
| Start date | Mar 1, 2004 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 21, 2005 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: